Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
Vasculitis
How would you manage a patient with GCA who had recurrence on tocilizumab and low dose prednisone?
Would you continue tocilizumab?
Related Questions
How would you treat a young patient who presents with coronary vasculitis and aortitis with persistently positive MPO but no other features of AAV?
How would you approach management of incidentally identified unilateral retinal vasculitis with subsequent labs revealing +P-ANCA?
Has anyone successfully gotten insurance approval for avacopan for ANCA-negative GPA?
Would you check ANCA titers in a patient with a history of PR-3-ANCA glomerulonephritis in remission and a stable creatinine but with recurrent microscopic hematuria?
How long do you continue PJP prophylaxis in a patient with GPA who is able to wean steroids and remains only on rituximab for maintenance therapy?
Would you use a reduced dose glucocorticoid tapering regimen for patients with vasculitis due to Sjögren’s syndrome treated with Rituximab?
Would you approach a patient with idiopathic bilateral sensorineural hearing loss and episcleritis as atypical Cogan’s syndrome even in the absence of MRI/ MRA changes and minimal elevation of inflammation markers?
Do you recommend PJP prophyalaxis as a rule in giant cell arteritis patients on high dose steroids?
How would you approach workup and management of a patient who has signs and symptoms consistent with GPA found to have a cavitary lung lesion however is ANCA negative and has no kidney disease.
Would you continue Rituximab infusions in a patient with GPA and renal involvement who has been in remission on Avacopan and Rituximab, but had PRES post Rituximab infusion?